Skip to content


  • Letter to the Editor
  • Open Access

Upregulated TCRζ improves cytokine secretion in T cells from patients with AML

  • 1,
  • 2,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 3,
  • 3,
  • 3,
  • 3 and
  • 1, 4Email author
Contributed equally
Journal of Hematology & Oncology20158:72

  • Received: 24 May 2015
  • Accepted: 5 June 2015
  • Published:


Previous studies indicated that upregulating TCRζ partially recovers T cell function in patients with leukemia. In this study, we characterized the cytokine profile of TCRζ-transfected T cells from acute myeloid leukemia (AML) patients by Quantibody®Array Glass Chip. Firstly, the significantly lower expression of TCRζ in CD3+/TCRζ+ cells from AML patients was found. Increased secretion of IL-2, IL-8, IL-10, IL-13, IFN-γ, TNF-α, GM-CSF, growth-regulated oncogene (GRO), MIP-1b, and regulated on activation, normal T cell expressed and secreted (RANTES) could be detected in T cells from AML patients after TCRζ upregulating. We concluded that upregulating TCRζ in T cells from AML can alter the secretion profile of cytokines and chemokine which are involved in T cell proliferation and activation.


  • Acute myeloid leukemia
  • T cells
  • TCRζ
  • Cytokine
  • Chemokine


Acute myeloid leukemia (AML) is an aggressive disease with an unfavorable prognosis [13]. T cell immunodeficiency is a common characteristic in hematological malignancies which may be due to defective TCRζ. Previous studies showed that TCRζupregulation could be induced in CD3+T cells from AML patients by IL-2, IL-7, and IL-12 [4]. In this study, we characterized the secretion profile of cytokines and chemokines related to T cell activation in TCRζ-IRES2-EGFP-transfected T cells from AML patients after TCRζupregulation.

First, significantly lower TCRζ expression in CD3+/TCRζ+ cells in AML (2.89 ± 2.6 %, n = 10) was found in comparison with healthy individuals (87.38 ± 15.67 %, n = 10) (p < 0.001) (Fig. 1a–c). This result further supported our previous finding that T cell immunodeficiency might be due to low TCRζ signaling in T cells [58].
Fig. 1
Fig. 1

Expression of CD3+/TCRζ+ cells in PBMCs and expression of TCRζ and Zap-70 in TCRζ-transfected CD3+ T cells from patients with AML. a MFI of CD3+/TCRζ+ in PBMCs from AML patients and healthy individuals (HI) (n =10). b Percentage of CD3+/TCRζ+ cells in PBMCs from a healthy individual. c Percentage of CD3+/TCRζ+ in PBMCs from a patient with AML. d TCRζ gene expression levels. e Zap-70 gene expression level in TCRζ-transfected CD3+ T cells and control cells. f TCRζ and Zap-70 protein expression in transfected CD3+ T cells from two AML samples and control cells

CD3+T cells were sorted from PBMCs from four AML patients (Additional file 1: Table S1) who had TCRζ deficiency and then transfected with TCRζ-IRES2-EGFP or IRES2-EGFP, respectively, by nucleofection [9]. Significant upregulation of TCRζ in TCRζ-IRES2-EGFP-transfected CD3+T cells was confirmed. Similar results were found in TCRζ downstream target factor Zap-70 (Fig. 1d–f). Thus, TCRζ gene transfection could directly upregulate TCRζ and Zap-70 in T cells from AML patients as previously found in CML [9].

Forced TCRζ chain expression can reverse TCR/CD3-mediated signaling abnormalities and defective IL-2 production in T cells [9, 10]. In this study, we used Quantibody®Array Glass Chip ( to quantitatively measure 20 human cytokines and chemokines in supernatants from TCRζ-IRES2-EGFP-transfected and IRES2-EGFP-transfected T cells from AML patients (Additional file 2). Increased secretion of IL-2, IL-8, IL-10, IL-13, IFN-γ, TNF-α, GM-CSF, growth-regulated oncogene (GRO), MIP-1b, and regulated on activation, normal T cell expressed and secreted (RANTES) and decreased secretion of IL-5 were found, while the secretion level of IL-1α, IL-1β, IL-4, IL-6, and IL-12 had no obvious change after TCRζupregulation. Moreover, the changes in the secretion levels of IL-10, MCP-1, MIP-1a, MMP-1, and VEGF were different in different AML samples (Fig. 2). After TCRζ transfection, the IFN-γ secretion level was increased in all samples in the TCRζ-IRES2-EGFP group (median 71.46 pg/mL) compared with the pIRES2-EGFP group (median 42 pg/mL) (P = 0.253) because the basal level of IFN-γ in T cells from different AML patients was relatively different, ranging from 18.89 to 169.41 pg/mL in control cells and from 54.02 to 335.33 pg/mL in TCRζ-IRES2-EGFP cells. Thus, it could be understood that the increased secretion of IFN-γ was not statistically different in this study even though there was an obvious change in its level. Similar characteristic was found in TNF-α secretion level (Additional file 3: Figure S1). Interestingly, we found that the level of GM-CSF was significantly increased (21.63 ± 15.19 pg/mL for TCRζ-IRES2-EGFP cells vs. 1.96 ± 1.83 pg/mL for pIRES2-EGFP cells) (p = 0.045) (Fig. 2), and IL-13, which is secreted by activated T cells and has synergistic effects with GM-CSF and G-CSF, was also upregulated after TCRζ gene transfection (Fig. 2). Recently, increasing data have shown that GM-CSF has a variety of effects on the immune system including the activation of T cells, maturation of dendritic cells, and the ability to promote humoral and cell-mediated responses; thus, it has been incorporated into immunotherapy strategies [11, 12].
Fig. 2
Fig. 2

Detection of the IL-2, IL-5, IL-8, IL-10, IL-13, RANTES, GM-CSF, MIP-1b, IFN-γ, and TNF-α level secreted from T cells from AML patients using Quantibody® array. a Fluorescence intensity (concentration) from laser scanner results. 1–4: four parallel wells for each sample. b The level of IL-2, IL-5, IL-8, IL-10, IL-13, RANTES, GM-CSF, and MIP-1b secreted from T cells from four cases with AML

In conclusion, we characterized the profile of cytokines and chemokines secretion in T cells after TCRζ gene transfection. Most cytokines related to T cell proliferation and activation, such as IL-2, IFN-γ, and TNF-α, had increased secretion after TCRζ upregulating. Moreover, some of the Th1-associated CC subfamily chemokines, such as CCL4 and CCL5, may contribute to T cell activation via TCRζ upregulation. These results may further support the idea of the effects of upregulating TCRζ in T cell immunity.




This study was supported by grants from the National Natural Science Foundation of China (Nos. 81100353, 81270604, and 81400109), the China Postdoctoral Science Foundation (No. 2013 M540685), the Guangdong Natural Science Foundation (Nos. S2013040016151 and S2013020012863), the Foundation for High-level Talents in Higher Education of Guangdong, China (No.[2013] 246-54), the Medical Science Foundation of Guangdong Province (Nos.A2011325 and B2013213), the Guangzhou Science and Technology Project foundation (201510010211), and the Fundamental Research Funds for the Central Universities (Nos. 21611447 and 21613313).

Authors’ Affiliations

Institute of Hematology, Medical College, Jinan University, Guangzhou, 510632, China
Department of Clinical Laboratory, First Affiliated Hospital, Jinan University, Guangzhou, 510632, China
Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, China
Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, 510632, China


  1. Löwenberg B. Prognostic factors in acute myeloid leukaemia. Best Pract Res ClinHaematol. 2001;14:65–75.View ArticleGoogle Scholar
  2. Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, et al. Azacitidine in patients with WHO-defined AML—results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J HematolOncol. 2013;6:32.Google Scholar
  3. van der Helm LH, Scheepers ER, Veeger NJ, Daenen SM, Mulder AB, van den Berg E, et al. Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol. 2013;6:29.PubMed CentralPubMedView ArticleGoogle Scholar
  4. Shi L, Chen S, Zha X, Xu Y, Xu L, Yang L, et al. Enhancement of the TCRζ expression, polyclonal expansion and activation of T cells from patients with AML after IL-2, IL-7 and IL-12 induction. DNA Cell Biol. 2015 Mar 10. [Epub ahead of print]Google Scholar
  5. Li Y. Alterations in the expression pattern of TCR zeta chain in T cells from patients with hematological diseases. Hematology. 2008;13:267–75.PubMedView ArticleGoogle Scholar
  6. Chen X, Woiciechowsky A, Raffegerst S, Schendel D, Kolb HJ, Roskrow M. Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol. 2000;111:817–25.PubMedGoogle Scholar
  7. Chen S, Yang L, Chen S, Li Y. TCR ζ chain expression in T cells from patients with CML. Hematology. 2009;14:95–100.PubMedView ArticleGoogle Scholar
  8. Huang L, Chen S, Zha X, Yang L, Li B, Yu Z, et al. Expression feature of CD3, FcεRIγ and Zap-70 in patients with chronic lymphocytic leukemia. Hematology. 2012;17:71–5.PubMedView ArticleGoogle Scholar
  9. Zha X, Chen S, Yang L, Shi L, Li B, Wu X, et al. Up-regulated TCRζ enhances interleukin-2 production in T-cells from patients with CML. DNA Cell Biol. 2012;31:1628–35.PubMed CentralPubMedView ArticleGoogle Scholar
  10. Nambiar MP, Fisher CU, Warke VG, Krishnan S, Mitchell JP, Delaney N, et al. Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48:1948–55.PubMedView ArticleGoogle Scholar
  11. Kaufman HL, Ruby CE, Hughes T, Slingluff Jr CL. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014;2:11.PubMed CentralPubMedView ArticleGoogle Scholar
  12. Xuan L, Wu X, Zhang Y, Fan Z, Ling Y, Huang F, et al. Granulocyte colony-stimulating factor affects the distribution and clonality of TRGV and TRDV repertoire of T cells and graft-versus-host disease. J Transl Med. 2011;9:215.PubMed CentralPubMedView ArticleGoogle Scholar


© Chen et al. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.